Response to "Hepatitis delta virus infection in the Middle East"
- PMID: 36205593
- DOI: 10.1111/liv.15451
Response to "Hepatitis delta virus infection in the Middle East"
Comment on
-
Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: A scoping review.Liver Int. 2023 Aug;43 Suppl 1:116-123. doi: 10.1111/liv.15338. Epub 2022 Jun 29. Liver Int. 2023. PMID: 35689428
-
Hepatitis delta virus infection in the Middle East.Liver Int. 2023 Jan;43(1):256. doi: 10.1111/liv.15450. Epub 2022 Oct 13. Liver Int. 2023. PMID: 36205630 No abstract available.
References
REFERENCES
-
- Lazarus JV, Al-Rifai A, Sanai FM, et al. Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: a scoping review. Liver Int. 2022;1-8. doi:10.1111/liv.15338
-
- Elbahrawy A, Ibrahim MK, Eliwa A, Alboraie M, Madian A, Aly HH. Current situation of viral hepatitis in Egypt. Microbiol and Immunol. 2021;65:352-372. doi:10.1111/1348-0421.12916
-
- Palom A, Rando-Segura A, Vico J, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Reports. 2022;4(10):100547. doi:10.1016/j.jhepr.2022.100547
-
- Jang TY, Wei YJ, Yeh ML, et al. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. J Formos Med Assoc. 2021;120(1 Pt 2):303-310. doi:10.1016/j.jfma.2020.10.002
-
- Lampertico P, Roulot D, Wedemeyer H. Bulevirtide with or without PEGIFNα for patients with compensated chronic hepatitis delta: from clinical trials to real life studies. J Hepatol. 2022; in press. doi:10.1016/j.jhep.2022.06.010
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
